Add time:08/29/2019         Source:sciencedirect.com

The aim of this study was to evaluate the effect of Tilmicosin (cas 108050-54-0) on echocardiographic measurements in donkeys. For this purpose, placebo and tilmicosin 30% (10 mg/kg) were administered subcutaneously to clinically healthy donkeys (n = 10) in a randomized prospective crossover study. Cardiac functions were evaluated by echocardiography using a 2.5-MHz curved-linear transducer at 0, 15, 30, 60, and 120 minutes after administration. Examination was carried out at 3 to 5 intercostal spaces, and measurements were obtained at three planes of images. Tilmicosin induced a significant decrease in fractional shortening percentage (FS%) at 30 minutes after treatment (P < .05), but ejection fraction percentage (EF%) and stroke volume (SV) were decreased at 60 minutes after treatment (P < .05). However, left ventricular volume at end-systole (LVESV) was increased when compared to placebo at 30, 60, and 90 minutes after administration (P < .05). Left ventricular volume at end-diastole (LVEDV) was increased at 60 minutes after treatment (P < .05). There was a positive correlation between FS% and EF% (r = 0.89, P < .01), LVESV and left ventricle internal diameter at systole (LVIDs; r = 0.97, P < .01), and SV and LVEDV (r = 0.56, P < .01). However, there was negative correlation between LVESV and EF% (r = −0.41, P < .05), ESV and FS% (r = −0.44, P < .05), LVIDs and EF% (r = −0.43, P < .05), and LVIDs and FS% (r = −0.47, P < .05). The present results indicate that tilmicosin could induce transient and short-lasting changes of cardiac function in donkeys.

We also recommend Trading Suppliers and Manufacturers of Tilmicosin (cas 108050-54-0). Pls Click Website Link as below: cas 108050-54-0 suppliers